系统性红斑狼疮患者中环鸟苷酸-腺苷酸合成酶的表达
本研究探讨cGAS通路是否参与SLE患者I型干扰素产生。SLE患者PBMC中cGAS表达显著高于正常对照(n=51 vs n=20,P<0.01),且与IFN评分正相关(P<0.001)。15%的SLE患者(7/48)可检测到cGAMP,而正常对照(0/19)和RA对照(0/22)均未检出;有cGAMP的SLE患者疾病活动度更高。
要点
- SLE患者PBMC中cGAS表达显著升高且与IFN评分正相关。
- 15%的SLE患者可检出cGAMP,正常和RA对照均未检出。
- 检出cGAMP的SLE患者疾病活动度更高。
核心结论
- 部分SLE患者中cGAS表达升高和cGAMP检出提示cGAS通路可能参与I型IFN产生。
- cGAS表达升高可能是暴露于I型IFN的结果,而cGAMP在疾病活动度高的患者中检出提示该通路可能参与疾病表达。
研究设计与样本
- 研究纳入SLE患者51例和正常对照20例检测cGAS mRNA表达,另检测cGAMP时SLE患者48例、正常对照19例和类风湿关节炎对照22例。
- SLE疾病活动度采用SELENA-SLEDAI评估,cGAS和ISG mRNA采用定量PCR检测,cGAMP采用超高效液相色谱串联质谱的多反应监测检测。
主要发现
- SLE患者PBMC中cGAS表达显著高于正常对照(n=51和n=20;P<0.01)。
- cGAS表达与IFN评分呈正相关(P<0.001)。
- 体外实验中cGAS在PBMC中的表达对I型IFN刺激呈剂量反应,符合其作为ISG的特征。
- 串联质谱靶向检测cGAMP在15%的SLE患者中检出(7/48),正常对照(0/19)和类风湿关节炎对照(0/22)均未检出。
- 有cGAMP的SLE患者疾病活动度高于无cGAMP者。
临床怎么用
- 对SLE患者可关注cGAS表达和cGAMP水平,其与I型IFN评分和疾病活动度相关,但尚未作为常规临床检测指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type I interferon (IFN) is implicated in the pathogenesis of systemic lupus erythematosus (SLE) and interferonopathies such as Aicardi-Goutières syndrome. A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus. The aim of this study was to determine whether the cGAS pathway contributes to type I IFN production in patients with SLE. METHODS: SLE disease activity was measured by the Safety of Estrogens in Lupus Erythematosus National Assessment version of the Systemic Lupus Erythematosus Disease Activity Index. Expression of messenger RNA for cGAS and IFN-stimulated genes (ISGs) was determined by quantitative polymerase chain reaction analysis. Cyclic GMP-AMP (cGAMP) levels were examined by multiple reaction monitoring with ultra-performance liquid chromatography tandem mass spectrometry. RESULTS: Expression of cGAS in peripheral blood mononuclear cells (PBMCs) was significantly higher in SLE patients than in normal controls (n = 51 and n = 20 respectively; P < 0.01). There was a positive correlation between cGAS expression and the IFN score (P < 0.001). The expression of cGAS in PBMCs showed a dose response to type I IFN stimulation in vitro, consistent with it being an ISG. Targeted measurement of cGAMP by tandem mass spectrometry detected cGAMP in 15% of the SLE patients (7 of 48) but none of the normal (0 of 19) or rheumatoid arthritis (0 of 22) controls. Disease activity was higher in SLE patients with cGAMP versus those without cGAMP. CONCLUSION: Increased cGAS expression and cGAMP in a proportion of SLE patients indicates that the cGAS pathway should be considered as a contributor to type I IFN production. Whereas higher cGAS expression may be a consequence of exposure to type I IFN, detection of cGAMP in patients with increased disease activity indicates potential involvement of this pathway in disease expression.
引用
- An J, Durcan L, Karr RM, et al. Expression of Cyclic GMP-AMP Synthase in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017. PMID: 27863149. doi:10.1002/art.40002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。